Early-onset pancreatic cancer patients benefit more from neoadjuvant chemotherapy and surgery Post author:admin Post published:August 7, 2025 Post category:uncategorized The incidence of early-onset pancreatic cancer (EOPC) is rising, yet optimal treatment strategies remain unclear. You Might Also Like Drinking any amount of alcohol may raise dementia risk September 23, 2025 Enfortumab vedotin and pembrolizumab show major benefits for urothelial carcinoma patients April 6, 2025 New pathway to combat cardiovascular disease identified November 5, 2023
Enfortumab vedotin and pembrolizumab show major benefits for urothelial carcinoma patients April 6, 2025